

Recommendations of the SEC (Urology) made in its 10th/25 meeting held on 18.12.2025 at CDSCO HQ New Delhi:

S. No	File Name & Drug Name, Strength	Firm Name	Recommendations
GCT Division			
1.	CT/144/25 Online Submission (52037) LY3502970	M/s Clinical Trials Eli Lilly and Company India Pvt. Ltd	The firm presented phase III clinical study protocol no.: J2A-MC-GZPS, amendment (a) dated 12-SEP-2025. After detailed deliberation, the committee opined that the firm shall submit phase II study report for proposed indication, i.e. stress urinary incontinence in obesity or overweight female subjects for further review by the committee in presence of two Endocrinologist experts. Dr. Sameer Trivedi didn't participate.